AI Verdict
RMTG has stronger fundamentals based on our AI analysis.
RNAZ vs RMTG Fundamental Comparison
| Metric | RNAZ | RMTG |
|---|---|---|
| Revenue | N/A | $3.5M |
| Net Income | $-21.2M | $-6.4M |
| Net Margin | N/A | -181.9% |
| ROE | -1,488.0% | N/A |
| ROA | -406.0% | -142.0% |
| Current Ratio | 1.60x | 0.09x |
| Debt/Equity | 1.57x | N/A |
| EPS | $-34.49 | $-0.51 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RNAZ vs RMTG: Frequently Asked Questions
Is RNAZ or RMTG a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RMTG has stronger fundamentals. RNAZ is rated STRONG SELL (88% confidence) while RMTG is rated STRONG SELL (95% confidence). This is not investment advice.
How does RNAZ compare to RMTG fundamentally?
Transcode Therapeutics, Inc. has ROE of -1,488.0% vs Regenerative Medical Technology Group Inc.'s N/A. Net margins are N/A vs -181.9% respectively.
Which stock pays higher dividends, RNAZ or RMTG?
RNAZ has a dividend yield of N/A or no dividend while RMTG has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RNAZ or RMTG for long term?
For long-term investing, consider that RNAZ has STRONG SELL rating with 88% confidence, while RMTG has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RNAZ vs RMTG?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RNAZ vs RMTG, the AI consensus favors RMTG based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.